Accueil   Diary - News   All news First-in-class immune checkpoint inhibitor program presented by OREGA Biotech at SITC meeting

First-in-class immune checkpoint inhibitor program presented by OREGA Biotech at SITC meeting

Preclinical-stage blocking antibodies against a novel immune checkpoint;
Increased response and survival to anti-PD1 in various PD1-resistant mouse models

 

Lyon, France, October 1st, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today the presentation of the preclinical data of its novel immune checkpoint program at the upcoming SITC meeting to be held November 6 -10, National Harbor, Maryland (USA).

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree